IMV Inc. (IMVIQ)

OTCMKTS: IMVIQ · Delayed Price · USD
0.0000
-0.0001 (-90.00%)
Mar 12, 2024, 11:22 AM EDT - Market closed

Company Description

IMV Inc. operates as a clinical-stage immuno-oncology company.

The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers.

The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer.

It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases.

The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

IMV Inc.
IMV Inc. logo
Country Nova Scotia, Canada
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 63
CEO Andrew Hall M.Sc.

Contact Details

Address:
130 Eileen Stubbs Ave., Suite 19
Dartmouth, A5 B3B 2C4
Nova Scotia, Canada
Phone 9024921819
Website imv-inc.com

Stock Details

Ticker Symbol IMVIQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001734768
ISIN Number CA44974L3011
SIC Code 2834

Key Executives

Name Position
Andrew Hall M.Sc. Chief Executive Officer and Director
Brittany Davison C.A., CPA Chief Accounting Officer, Corporate Secretary and Director
Dr. Jeremy R. Graff Ph.D. Chief Scientific Officer
Delphine Davan Senior Director of Communications and Investor Relations
Stephan Fiset M.B.A., M.Sc. Vice President of Clinical Research

Latest SEC Filings

Date Type Title
Sep 22, 2023 15-12G Securities registration termination
Sep 22, 2023 F-10POS Filing
Sep 22, 2023 F-10POS Filing
Sep 22, 2023 F-10POS Filing
Sep 22, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Sep 22, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Sep 22, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Sep 22, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Sep 22, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 26, 2023 6-K Report of foreign issuer